Shares of uniQure NV (NASDAQ:QURE) have earned an average recommendation of “Buy” from the eleven research firms that are covering the stock. One analyst has rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $27.75.

Several research firms have recently issued reports on QURE. Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a report on Thursday, July 28th. Jefferies Group set a $28.00 target price on shares of uniQure NV and gave the stock a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research cut shares of uniQure NV from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. Chardan Capital restated a “buy” rating on shares of uniQure NV in a report on Monday, July 18th. Finally, Piper Jaffray Cos. set a $16.00 target price on shares of uniQure NV and gave the stock a “buy” rating in a report on Friday, August 19th.

A number of large investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. increased its stake in uniQure NV by 5.8% in the first quarter. UBS Asset Management Americas Inc. now owns 345,403 shares of the company’s stock worth $4,103,000 after buying an additional 18,803 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in uniQure NV during the second quarter worth about $122,000. Acadian Asset Management LLC bought a new stake in uniQure NV during the second quarter worth about $804,000. Quantitative Systematic Strategies LLC bought a new stake in uniQure NV during the second quarter worth about $165,000. Finally, Princeton Alpha Management LP bought a new stake in uniQure NV during the second quarter worth about $120,000. Institutional investors own 31.68% of the company’s stock.

Shares of uniQure NV (NASDAQ:QURE) opened at 8.30 on Thursday. uniQure NV has a 12-month low of $6.63 and a 12-month high of $22.79. The firm’s market capitalization is $208.57 million. The stock’s 50 day moving average price is $7.36 and its 200-day moving average price is $8.84.

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.